AUSTRALIAN life sciences company QBiotics has announced two senior appointments to its medical leadership team.
Hong Kong-based physician Professor Victoria Elegant has been appointed Chief Medical Officer (CMO) and will oversee the general medical and clinical aspects of QBiotics' drug development programs.
Meanwhile, QBiotics Clinical Advisory Board member and senior oncologist Professor Aurelian Marabelle, based in Paris, has been appointed consultant and key adviser to the company's oncology drug development program.
QBiotics' current clinical focus is on novel treatments for cancer and debilitating chronic wounds, with its lead oncology drug, tigilanol tiglate, currently undergoing trials.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jan 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jan 25
